A multicenter phase II trial of carboplatin and cetuximab for treatment of advanced nonsmall cell lung cancer

Academic Article


  • Purpose: To investigate the activity of carboplatin and cetuximab in NSCLC. Patients and Methods: This was a single arm, multicenter phase II trial, and the primary objective was response rate. Results: The overall response rate observed was 9% (95% confidence interval [CI], 3-19), the progression-free survival was 2.9 months (95% CI, 1.9-3.6), the median overall survival was 8.2 months (95% CI, 4.9-10.5), and 1-year survival rate was 33% (95% CI, 21-45). Conclusion: The combination of carboplatin and cetuximab demonstrated lower activity than double agent platinum-based therapy and does not warrant further development.
  • Published In

    Digital Object Identifier (doi)

    Pubmed Id

  • 26778525
  • Author List

  • Stinchcombe TE; Bradford DS; Hensing TA; LaRocca RV; Saleh M; Evans T; Bakri K; Socinski MA
  • Start Page

  • 208
  • End Page

  • 215
  • Volume

  • 28
  • Issue

  • 2